A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes
Eli Lilly and Company
Summary
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
Eligibility
- Age range
- 18–75 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Have type 2 diabetes * Have an HbA1c ≥7.5% to ≤10.5% at screening * Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening * Diet and exercise * Stable dose of metformin * Sodium-glucose cotransporter-2 (SGLT2) inhibitor * Have had a stable body weight (\<5% body weight gain and/or loss) for the 3 months prior to screening * Have a BMI of 27 or greater at screening Exclusion Criteria: * Have any form of diabetes other than type 2 diabetes * Have a prior or planned surgical treatment for obesity, except prio…